These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15776818)

  • 1. Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl beta-cyclodextrin system.
    Govindarajan R; Nagarsenker MS
    Pharm Dev Technol; 2005; 10(1):105-14. PubMed ID: 15776818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation.
    Wang HB; Yang FF; Gai XM; Cheng BC; Li JY; Pan H; Yang XG; Pan WS
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1460-1471. PubMed ID: 28402143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
    Cirri M; Rangoni C; Maestrelli F; Corti G; Mura P
    Drug Dev Ind Pharm; 2005 Aug; 31(7):697-707. PubMed ID: 16207617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly(alkyl-cyanoacrylate) nanoparticles.
    Zhao X; Li W; Luo Q; Zhang X
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):61-7. PubMed ID: 23700219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets.
    Jug M; Bećirević-Laćan M
    Eur J Pharm Sci; 2004 Feb; 21(2-3):251-60. PubMed ID: 14757497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery.
    Vega E; Egea MA; Calpena AC; Espina M; García ML
    Int J Nanomedicine; 2012; 7():1357-71. PubMed ID: 22457594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system.
    Govindarajan R; Nagarsenker MS
    J Pharm Pharmacol; 2004 Jun; 56(6):725-33. PubMed ID: 15231037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug/cyclodextrin solid systems in the design of hydrophilic matrices: a strategy to modulate drug delivery rate.
    Miro A; Quaglia F; Giannini L; Cappello B; La Rotonda MI
    Curr Drug Deliv; 2006 Oct; 3(4):373-8. PubMed ID: 17076639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole.
    Pacheco PA; Rodrigues LNC; Ferreira JFS; Gomes ACP; Veríssimo CJ; Louvandini H; Costa RLD; Katiki LM
    Parasitol Res; 2018 Mar; 117(3):705-712. PubMed ID: 29327323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the bioavailability of flurbiprofen and its beta-cyclodextrin inclusion complex in four different doses upon oral administration to rats.
    Muraoka A; Tokumura T; Machida Y
    Eur J Pharm Biopharm; 2004 Nov; 58(3):667-71. PubMed ID: 15451543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulated dissolution rate from the inclusion complex of antichagasic benznidazole and cyclodextrin using hydrophilic polymer.
    Sá-Barreto LC; Gustmann PC; Garcia FS; Maximiano FP; Novack KM; Cunha-Filho MS
    Pharm Dev Technol; 2013; 18(5):1035-41. PubMed ID: 22200091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component.
    Basavaraj S; Sihorkar V; Shantha Kumar TR; Sundaramurthi P; Srinivas NR; Venkatesh P; Ramesh M; Kumar Singh S
    Pharm Dev Technol; 2006; 11(4):443-51. PubMed ID: 17101515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin.
    Mura P; Faucci MT; Bettinetti GP
    Eur J Pharm Sci; 2001 May; 13(2):187-94. PubMed ID: 11297903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system.
    Cappello B; De Rosa G; Giannini L; La Rotonda MI; Mensitieri G; Miro A; Quaglia F; Russo R
    Int J Pharm; 2006 Aug; 319(1-2):63-70. PubMed ID: 16650700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin.
    Nair AB; Attimarad M; Al-Dhubiab BE; Wadhwa J; Harsha S; Ahmed M
    Drug Deliv; 2014 Nov; 21(7):540-7. PubMed ID: 24215288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and
    Dudhipala N; Ettireddy S; Youssef AAA; Puchchakayala G
    Nanotheranostics; 2023; 7(1):117-127. PubMed ID: 36593793
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxypropyl-β-Cyclodextrin and β-Cyclodextrin as Tablet Fillers for Direct Compression.
    Conceição J; Adeoye O; Cabral-Marques HM; Sousa Lobo JM
    AAPS PharmSciTech; 2018 Aug; 19(6):2710-2718. PubMed ID: 29978292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage.
    Nagarsenker MS; Joshi MS
    Drug Dev Ind Pharm; 2005 Jan; 31(2):169-78. PubMed ID: 15773284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats.
    Nagarsenker MS; Meshram RN; Ramprakash G
    J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.